Uptravi vs. Opsumit

Uptravi (selexipag) and Opsumit (macitentan) are used to treat pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression.

Uptravi and Opsumit belong to different drug classes. Uptravi is a prostacyclin receptor agonist and Opsumit is an endothelin receptor antagonist.

Side effects of Uptravi and Opsumit that are similar include headache and low levels of iron in the blood (anemia).

Side effects of Uptravi that are different from Opsumit include diarrhea, jaw pain, nausea, muscle pain, vomiting, pain in extremities, flushing (warmth, redness, or tingly feeling), joint pain, decreased appetite, and rash.

Side effects of Opsumit that are different from Uptravi include common cold-like symptoms (stuffy nose or sore throat), bronchitis, flu, and urinary tract infection (UTI).

Both Uptravi and Opsumit may interact with rifampin.

Uptravi may also interact with gemfibrozil, teriflunomide, and deferasirox.

Opsumit may also interact with ketoconazole and ritonavir.

Common side effects of Uptravi include:

Side effects of Uptravi include:

• headache,
• diarrhea,
• jaw pain,
• nausea,
• muscle pain,
• vomiting,
• pain in extremities,
• flushing (warmth, redness, or tingly feeling),
• joint pain,
• low levels of iron in the blood (anemia),
• decreased appetite, or
• rash

Common side effects of Opsumit include:

• low red blood cell count (anemia),
• common cold-like symptoms (stuffy nose or sore throat),
• bronchitis,
• headache,
• flu and
• urinary tract infection.

Uptravi (selexipag) is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Opsumit (macitentan) is an endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression.

Uptravi may interact with strong inhibitors of CYP2C8 (e.g., gemfibrozil). Tell your doctor all medications and supplements you use.

Opsumit may interact with rifampin, ketoconazole, and ritonavir. Tell your doctor all medications and supplements you use. Opsumit is not recommended for use during pregnancy. It may harm a fetus.

The starting dose of Uptravi is 200 mcg twice daily. Increase the dose of Uptravi by 200 mcg twice daily at weekly intervals to the highest tolerated dose up to 1600 mcg twice daily.

The recommended dosage of Opsumit is 10 mg once daily for oral administration.